KARACHI – In a significant leap toward finding a permanent cure for HIV/AIDS, scientists have reported a major breakthrough using a novel CAR-T cell therapy. Preliminary human trials indicate that this one-time treatment can effectively control the virus without the need for lifelong daily medication.
The Mechanism: Re-engineering the Immune System
According to a report by Reuters, the research focuses on modifying a patient’s own immune cells to locate and destroy the HIV virus. In the Phase 1 trial, researchers extracted T-cells from patients, genetically engineered them in a laboratory to target specific binding sites of the virus (CD4 and CCR5), and then re-infused them into the body.
Key Findings of the Study
The clinical trial, involving researchers from the University of California and Case Western Reserve University, yielded several critical insights. Two out of three patients who received a standard dose of CAR-T cells maintained “undetectable or very low” levels of HIV even after stopping their regular antiretroviral therapy (ART). One patient has remained in stable condition for over two years, while another has maintained viral suppression for nearly a year. Unlike CAR-T treatments used for cancer, HIV patients did not experience severe side effects like Cytokine Release Syndrome.
Expert Insights
Dr. Steven Deeks, lead researcher and professor at UC San Francisco, noted that the most successful participants were those who had been diagnosed and treated very early.
“The CAR-T cells disappeared after a few weeks, so we are now working to understand the exact mechanism of why some patients showed such a positive long-term response,” Dr. Deeks explained.
Dr. Boro Dropulic, Executive Director of the non-profit Caring Cross, emphasized the ultimate goal of the project: “Our aim is to make these high-tech therapies affordable and accessible to the millions living with HIV.”
The Global Impact
Currently, approximately 41 million people worldwide live with HIV. While modern Antiretroviral Therapy (ART) has made HIV a manageable condition, it requires a lifetime commitment to daily pills. This new cell therapy offers hope for a “functional cure,” potentially freeing patients from daily medication.
Future Outlook
While the results are historic, researchers cautioned that further studies are needed to confirm the findings and determine which patient profiles benefit most from this intervention. The results were presented at the annual meeting of the American Society of Gene and Cell Therapy in Boston.
